China Osteoarthritis Therapeutics Market Size & Outlook

The osteoarthritis therapeutics market in China is expected to reach a projected revenue of US$ 885.9 million by 2030. A compound annual growth rate of 11% is expected of China osteoarthritis therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$426.3
Forecast, 2030 (US$M)
$885.9
CAGR, 2024 - 2030
11%
Report Coverage
China

China osteoarthritis therapeutics market, 2018-2030 (US$M)

China

China osteoarthritis therapeutics market highlights

  • The China osteoarthritis therapeutics market generated a revenue of USD 426.3 million in 2023 and is expected to reach USD 885.9 million by 2030.
  • The China market is expected to grow at a CAGR of 11% from 2024 to 2030.
  • In terms of segment, viscosupplementation agents was the largest revenue generating drug type in 2023.
  • Viscosupplementation Agents is the most lucrative drug type segment registering the fastest growth during the forecast period.

Osteoarthritis therapeutics market data book summary

Market revenue in 2023USD 426.3 million
Market revenue in 2030USD 885.9 million
Growth rate11% (CAGR from 2023 to 2030)
Largest segmentViscosupplementation agents
Fastest growing segmentViscosupplementation Agents
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationViscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids, Others Drug Type
Key market players worldwideGlaxoSmithKline Consumer Healthcare (GSK CH India), Sanofi SA, Pfizer Inc, Bayer AG, Zimmer Biomet Holdings Inc, Novartis AG ADR, Anika Therapeutics Inc, Assertio Holdings Inc, Bioventus Inc Class A

Other key industry trends

  • In terms of revenue, China accounted for 5.0% of the global osteoarthritis therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China osteoarthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 885.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Osteoarthritis Therapeutics Market Scope

Osteoarthritis therapeutics market segmentation & scope
Viscosupplementation Agents
Naproxen
Aspirin
Diclofenac
Ibuprofen
Celecoxib
Meloxicam
Piroxicam
Ketoprofen
Other NSAIDs
Duloxetine
Acetaminophen
Corticosteroids
Others Drug Type
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others Anatomy
Hyaluronic Acid Injections
Corticosteroid Injections
Platelet-rich Plasma (PRP) Injections
Placental Tissue Matrix (PTM) Injections
Acetylsalicylic Acid (ASA) Injections
Other Parenteral Routes
Topical Route
Oral Route
Prescription Drugs
Over-the-Counter Drugs
Hospital Pharmacies
Retail Pharmacies
Other End-users

Osteoarthritis Therapeutics Market Companies

Name Profile # Employees HQ Website

China osteoarthritis therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to osteoarthritis therapeutics market will help companies and investors design strategic landscapes.


Viscosupplementation agents was the largest segment with a revenue share of 36.62% in 2023. Horizon Databook has segmented the China osteoarthritis therapeutics market based on viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, corticosteroids, others drug type covering the revenue growth of each sub-segment from 2018 to 2030.


  • China Osteoarthritis Therapeutics Drug Type Outlook (Revenue, USD Million, 2018-2030)
    • Viscosupplementation Agents
    • Nonsteroidal Anti-inflammatory Drugs
      • Naproxen
      • Aspirin
      • Diclofenac
      • Ibuprofen
      • Celecoxib
      • Meloxicam
      • Piroxicam
      • Ketoprofen
      • Other NSAIDs
    • Analgesics
      • Duloxetine
      • Acetaminophen
    • Corticosteroids
    • Others Drug Type
  • China Osteoarthritis Therapeutics Anatomy Outlook (Revenue, USD Million, 2018-2030)
    • Knee Osteoarthritis
    • Hip Osteoarthritis
    • Hand Osteoarthritis
    • Others Anatomy
  • China Osteoarthritis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
    • Parenteral Route
      • Hyaluronic Acid Injections
      • Corticosteroid Injections
      • Platelet-rich Plasma (PRP) Injections
      • Placental Tissue Matrix (PTM) Injections
      • Acetylsalicylic Acid (ASA) Injections
      • Other Parenteral Routes
    • Topical Route
    • Oral Route
  • China Osteoarthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2018-2030)
    • Prescription Drugs
    • Over-the-Counter Drugs
  • China Osteoarthritis Therapeutics End Use Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Other End-users

Reasons to subscribe to China osteoarthritis therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China osteoarthritis therapeutics market databook

  • Our clientele includes a mix of osteoarthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China osteoarthritis therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China osteoarthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China osteoarthritis therapeutics market size, by drug type, 2018-2030 (US$M)

China Osteoarthritis Therapeutics Market Outlook Share, 2023 & 2030 (US$M)

China osteoarthritis therapeutics market size, by drug type, 2018-2030 (US$M)

Related regional statistics

No records

No related regions found.

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more